目的 探讨索拉非尼联合奥沙利铂对人肝癌BEL-7402细胞的抑制作用.方法选取人肝癌细胞株BEL-7402,用奥沙利铂和索拉非尼单药或联合(含不同给药顺序)作用于细胞,观察最佳抑制效果.MTT法检测奥沙利铂和索拉非尼分别对肝癌BEL-7402细胞的抑制作用并计算半数抑制浓度(IC50)；电镜下观察细胞形态和超微结构的改变；流式细胞仪检测细胞周期分布及细胞凋亡的变化.结果 奥沙利铂单药及联合索拉非尼组BEL-7402细胞出现S期、G2/M期阻滞,索拉非尼单药组仅出现S期阻滞.先用奥沙利铂联合组的BEL-7402细胞凋亡率最高,为(40.94±4.62)%,其次为先用索拉非尼联合组的凋亡率( 30.02 +4.15)%,联合组的BEL-7402细胞凋亡率均高于索拉非尼单药组(P＜(0.05).结论人肝癌BEL-7402细胞体外对索拉非尼和奥沙利铂均高度敏感,两药联合应用对肝癌细胞有协同抑制作用,且先用奥沙利铂联合给药的效果更好.%Objective To observe effects of sorafenib combined with oxaliplatin ( OX A) on human hepatocellular carcinoma cell line BEL-7402. Methods In order to find the best effect, human hepatocellular carcinoma cell line BEL-7402 was treated with sorafenib and OXA alone or in combination according to different sequences. Median inhibition concentration ( IC50) was calculated by MTT assay for OXA and sorafenib in BEL-7402. Altered cellular morphism and infrastructure of the treated cells were observed under transmission electron microscope, and cell cycle distribution and altered apoptosis were analyzed by flow cytometry. Results S and G,/M phase arrest was observed in the three regimens containing OXA (OXA alone and two dosing sequences of combination) , while S phase arrest was found in the regimen containing sorafenib alone. The highest apoptosis rate was (40. 94 + 4. 62) % in OXA and sorafenib combination ( OXA prior used) , dwarfing (30. 02 ± 4. 15)% of sorafenib and OXA combination ( sorafenib prior used) , while it of either combination were superior to that of sorafenib alone ( P < 0. 05 ). Conclusion Human hepatocellular carcinoma cell BEL-7402 is highly sensitive to both sorafenib and OXA, which may cooperate in combination for synergistic inhibition on hepatocellular carcinoma cells with better effect in the dosing sequence of OXA followed by sorafenib.
展开▼
